EXEL Exelixis, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

EXEL [NASD]

Exelixis, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	26.63	EPS (ttm)	0.89	Insider Own	1.30%	Shs Outstand	307.81M	Perf Week	-8.06%
Market Cap	7.15B	Forward P/E	28.87	EPS next Y	0.82	Insider Trans	-23.20%	Shs Float	298.82M	Perf Month	9.00%
Income	281.60M	PEG	0.58	EPS next Q	0.06	Inst Own	84.10%	Short Float	3.31%	Perf Quarter	4.40%
Sales	998.40M	P/S	7.16	EPS this Y	-53.80%	Inst Trans	2.14%	Short Ratio	4.62	Perf Half Y	33.54%
Book/sh	5.96	P/B	3.98	EPS next Y	83.48%	ROA	14.70%	Target Price	31.46	Perf Year	31.87%
Cash/sh	4.03	P/C	5.89	EPS next 5Y	46.00%	ROE	16.40%	52W Range	13.67 - 27.80	Perf YTD	34.68%
Dividend	-	P/FCF	19.20	EPS past 5Y	22.50%	ROI	17.30%	52W High	-14.64%	Beta	1.29
Dividend %	-	Quick Ratio	9.70	Sales past 5Y	107.60%	Gross Margin	96.30%	52W Low	73.59%	ATR	1.03
Employees	617	Current Ratio	9.80	Sales Q/Q	8.00%	Oper. Margin	32.20%	RSI (14)	50.37	Volatility	4.84% 4.55%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-16.30%	Profit Margin	28.20%	Rel Volume	0.53	Prev Close	23.84
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 06 AMC	Payout	0.00%	Avg Volume	2.14M	Price	23.73
Recom	2.00	SMA20	1.92%	SMA50	2.40%	SMA200	11.16%	Volume	1,137,736	Change	-0.46%

Mar-04-20

Initiated

Barclays

Overweight

$26

Jan-13-20

Initiated

SunTrust

Buy

$31

Nov-13-19

Initiated

BofA/Merrill

Buy

$22

Mar-18-19

Upgrade

Morgan Stanley

Underweight → Equal-Weight

Sep-17-18

Initiated

Goldman

Neutral

$22

Sep-10-18

Initiated

Morgan Stanley

Underweight

$19

May-11-18

Reiterated

Needham

Buy

$33 → $30

Oct-17-17

Reiterated

RBC Capital Mkts

Outperform

$33 → $39

Oct-17-17

Reiterated

Needham

Buy

$30 → $33

Oct-16-17

Reiterated

SunTrust

Buy

$32 → $35

Sep-22-17

Downgrade

Leerink Partners

Outperform → Mkt Perform

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$32

Sep-12-17

Reiterated

Needham

Buy

$28 → $30

Jul-14-17

Initiated

SunTrust

Buy

$33

Mar-31-17

Initiated

Needham

Buy

$28

Mar-16-17

Initiated

Oppenheimer

Perform

Feb-28-17

Downgrade

Stifel

Buy → Hold

$21 → $22

Nov-03-16

Initiated

Deutsche Bank

Buy

$17

Oct-10-16

Upgrade

Piper Jaffray

Neutral → Overweight

Sep-15-16

Reiterated

Stifel

Buy

$12 → $15

Sep-21-20 10:20AM	Exelixis Announces Results From Two Renal Cell Carcinoma Cohorts of the COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab Business Wire
05:51AM	The Best Stocks to Invest $1,000 In When the Market Is Falling Motley Fool
Sep-19-20 12:30PM	Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial Business Wire
Sep-18-20 06:05PM	Bristol Myers' Opdivo with Exelixis drug cuts kidney cancer death risk -study Reuters
Sep-15-20 08:00AM	Exelixis and Iconic Therapeutics Announce Promising Preclinical Data That Support Best-in-Class Potential for ICON-2 in Treatment of Solid Tumors Business Wire
Sep-14-20 08:00AM	Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020 Business Wire +13.81%
Sep-13-20 06:52AM	Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash Motley Fool
Sep-09-20 12:44PM	Exelixis Inks a Couple of Deals to Develop Novel ADCs for Cancer Zacks
Sep-08-20 11:57PM	Hedge Funds Have Never Been This Bullish On Exelixis, Inc. (EXEL) Insider Monkey
04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in September Business Wire
11:41AM	3 Healthcare Stocks to Buy in a Stock Market Crash Motley Fool
08:05AM	Exelixis and NBE-Therapeutics Enter Into Exclusive Collaboration and License Option Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer Business Wire
08:01AM	Exelixis and Catalent Enter into Collaboration, License, and Exclusive Option Agreement to Develop Antibody-Drug Conjugates Leveraging SMARTag® Bioconjugation Technology Business Wire
Sep-05-20 11:31AM	Exelixis (EXEL) Down 9.4% Since Last Earnings Report: Can It Rebound? Zacks
Aug-25-20 10:02AM	Exelixis Files for Cabometyx Combo in First-Line Kidney Cancer Zacks
07:57AM	Why Exelixis' (NASDAQ:EXEL) CEO Pay Matters Simply Wall St.
Aug-24-20 08:00AM	Exelixis Announces Submission of Supplemental New Drug Application to U.S. Food and Drug Administration for CABOMETYX® (cabozantinib) in Combination With Opdivo® (nivolumab) for Advanced Renal Cell Carcinoma Business Wire
Aug-07-20 10:32AM	Exelixis' (EXEL) Q2 Earnings and Revenues Surpass Estimates Zacks
Aug-06-20 08:20PM	Exelixis (EXEL) Surpasses Q2 Earnings and Revenue Estimates Zacks
04:05PM	Exelixis Announces Second Quarter 2020 Financial Results and Provides Corporate Update Business Wire
Jul-30-20 12:33PM	Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-29-20 04:05PM	Exelixis to Release Second Quarter 2020 Financial Results on Thursday, August 6, 2020 Business Wire
Jul-23-20 12:20PM	Will Exelixis (EXEL) Gain on Rising Earnings Estimates? Zacks
Jul-22-20 12:32PM	Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for Zacks
11:40AM	EXEL vs. RGEN: Which Stock Should Value Investors Buy Now? Zacks
Jul-21-20 12:10PM	Can Exelixis (EXEL) Keep the Earnings Surprise Streak Alive? Zacks
10:00AM	Exelixis Starts Study on Cabometyx Combo in Kidney Cancer Zacks
Jul-20-20 12:43PM	Could The Exelixis, Inc. (NASDAQ:EXEL) Ownership Structure Tell Us Something Useful? Simply Wall St.
08:00AM	Exelixis Announces Initiation of CONTACT-03 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Renal Cell Carcinoma Business Wire
Jul-13-20 10:45AM	Did Hedge Funds Make The Right Call On Exelixis, Inc. (EXEL) ? Insider Monkey
Jul-10-20 07:16AM	2 Stocks to Buy if You're Worried About Another Market Crash Motley Fool
05:51AM	Got $3,000? 3 Growth Stocks You Won't Regret Buying Motley Fool
Jul-03-20 12:36PM	5 Booming Biotech Stocks to Buy Kiplinger
Jun-30-20 08:00AM	Exelixis Announces Initiation of CONTACT-02 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Castration-Resistant Prostate Cancer Business Wire
Jun-22-20 11:02PM	Exelixis (EXEL) in Focus: Stock Moves 7.6% Higher Zacks
Jun-18-20 04:05PM	Exelixis to Webcast Virtual Fireside Chat as Part of the BofA Securities Napa Biopharma Conference on June 24, 2020 Business Wire
Jun-17-20 01:42PM	3 Stocks Growing Capex Fast GuruFocus.com
Jun-12-20 10:15AM	Hedge Funds Going Back and Forth About Exelixis, Inc. (EXEL) Insider Monkey
Jun-11-20 08:00AM	Exelixis Announces Initiation of CONTACT-01 Phase 3 Pivotal Trial of Cabozantinib in Combination With Atezolizumab in Previously Treated Metastatic Non-small Cell Lung Cancer Business Wire -6.53%
Jun-04-20 11:31AM	Exelixis (EXEL) Down 11.5% Since Last Earnings Report: Can It Rebound? Zacks
Jun-03-20 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in June Business Wire
Jun-02-20 02:59AM	Edited Transcript of EXEL earnings conference call or presentation 5-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-28-20 06:58AM	Is There An Opportunity With Exelixis, Inc.'s (NASDAQ:EXEL) 49% Undervaluation? Simply Wall St.
May-20-20 01:30PM	3 Charts That Suggest Biotech Stocks Are Headed Higher Investopedia
May-13-20 05:00PM	Exelixis Announces Results From COSMIC-021 Trial of Cabozantinib in Combination With Atezolizumab in Multiple Advanced Solid Tumor Types Business Wire
09:54AM	Better Buy: bluebird bio vs. Exelixis Motley Fool
May-06-20 04:05PM	Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May Business Wire
11:40AM	Exelixis (EXEL) Q1 Earnings and Revenues Surpass Estimates Zacks
01:01AM	Exelixis Inc (EXEL) Q1 2020 Earnings Call Transcript Motley Fool
May-05-20 06:25PM	Exelixis (EXEL) Q1 Earnings and Revenues Beat Estimates Zacks
04:05PM	Exelixis Announces First Quarter 2020 Financial Results and Provides Corporate Update Business Wire
03:00PM	Exelixis, Inc. to Host Earnings Call ACCESSWIRE
May-01-20 01:14PM	Exelixis Charts Are Pointed Higher, Look to Buy a Dip TheStreet.com
Apr-28-20 12:33PM	Earnings Preview: Exelixis (EXEL) Q1 Earnings Expected to Decline Zacks
Apr-22-20 10:30AM	Biotech Stock Roundup: ALXN, MRNA Up on Coronavirus Treatment Updates, & More Zacks
09:00AM	How Does Exelixis's (NASDAQ:EXEL) P/E Compare To Its Industry, After Its Big Share Price Gain? Simply Wall St.
Apr-21-20 04:05PM	Exelixis to Release First Quarter 2020 Financial Results on Tuesday, May 5, 2020 Business Wire
12:59PM	Company News for Apr 21, 2020 Zacks
12:43PM	Exelixis Stock Strength Jumps On Positive Cancer Treatment Results Investor's Business Daily
Apr-20-20 06:01PM	How this East Bay biotech pushed past the 'negativity' with a big boost to its kidney cancer drug American City Business Journals +21.27%
04:19PM	This Biotech Stock Just Blew Into A Profit-Taking Zone Here's Why Investor's Business Daily
11:03AM	Kidney Cancer Drug From Bristol-Myers and Exelixis Meets Key Phase III Endpoint TheStreet.com
07:12AM	Exelixis, Bristol-Myers stocks get a boost from upbeat trial results of a Kidney cancer treatment MarketWatch
06:59AM	CORRECTED-Bristol Myers says Opdivo performs well in kidney, lung cancer trials Reuters
06:59AM	Bristol Myers Squibb and Exelixis Announce Positive Topline Results from Pivotal Phase 3 CheckMate -9ER Trial Evaluating Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) in Previously Untreated Advanced Renal Cell Carcinoma Business Wire
Apr-09-20 11:40AM	EXEL vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
Apr-08-20 04:05PM	Exelixis to Webcast Virtual Fireside Chat as Part of the Needham Healthcare Conference on April 15, 2020 Business Wire +5.79%
Mar-26-20 03:41PM	Were These Hedge Funds Right About Selling Exelixis, Inc. (EXEL)? Insider Monkey +9.58%
11:30AM	Why Is Exelixis (EXEL) Down 15.6% Since Last Earnings Report? Zacks
Mar-25-20 03:01AM	Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) Tablets for the Treatment of Curatively Unresectable or Metastatic Renal Cell Carcinoma Business Wire
Mar-24-20 11:40AM	EXEL vs. ILMN: Which Stock Should Value Investors Buy Now? Zacks
Mar-17-20 07:02AM	A Sliding Share Price Has Us Looking At Exelixis, Inc.'s (NASDAQ:EXEL) P/E Ratio Simply Wall St.
Mar-02-20 04:05PM	Exelixis Announces George A. Scangos, Ph.D. to Retire From Its Board of Directors Business Wire
Feb-27-20 06:19AM	Exelixis, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next Simply Wall St.
12:31AM	Edited Transcript of EXEL earnings conference call or presentation 25-Feb-20 10:00pm GMT Thomson Reuters StreetEvents
Feb-26-20 04:05PM	Exelixis Announces Webcasts of Investor Conference Presentations in March Business Wire
10:03AM	Exelixis (EXEL) Beats on Earnings, Misses on Sales in Q4 Zacks
Feb-25-20 06:35PM	Exelixis (EXEL) Tops Q4 Earnings Estimates Zacks
04:06PM	Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer Business Wire
04:05PM	Exelixis Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Business Wire
Feb-21-20 11:30AM	Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-19-20 07:28AM	The Exelixis (NASDAQ:EXEL) Share Price Has Soared 689%, Delighting Many Shareholders Simply Wall St.
Feb-12-20 04:05PM	Exelixis to Release Fourth Quarter and Full Year 2019 Financial Results on Tuesday, February 25, 2020 Business Wire
02:10PM	3 Mid-Cap Growth Stocks to Buy InvestorPlace
Feb-11-20 05:50PM	Exelixis (EXEL) Outpaces Stock Market Gains: What You Should Know Zacks
07:23AM	The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 05:00PM	Exelixis Announces Encouraging Results for Cabozantinib in Combination With Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Business Wire
Feb-04-20 05:50PM	Exelixis (EXEL) Gains But Lags Market: What You Should Know Zacks
Jan-29-20 08:30AM	The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
02:01AM	Exelixis Announces Partner Takeda Files New Drug Application in Japan for CABOMETYX® (cabozantinib) for Advanced Hepatocellular Carcinoma Business Wire
Jan-28-20 09:52AM	How Alameda again became a biotech hotspot American City Business Journals
Jan-27-20 08:07AM	Roche Submits Application for Tecentriq-Avastin Combo in HCC Zacks
Jan-24-20 07:30AM	Exelixis Announces Results for Combination of Cabozantinib and Nivolumab With or Without Ipilimumab in Advanced Hepatocellular Carcinoma Business Wire -7.92%
Jan-21-20 06:10PM	How this East Bay biotech went from debt to expansion American City Business Journals
Jan-17-20 11:40AM	GILD or EXEL: Which Is the Better Value Stock Right Now? Zacks
Jan-14-20 07:38AM	Does Exelixis, Inc. (NASDAQ:EXEL) Have A Good P/E Ratio? Simply Wall St. +6.39%
Jan-13-20 12:10PM	Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? Zacks
Jan-12-20 04:00PM	Exelixis Outlines Key Priorities and Anticipated Milestones for 2020-21, Announces Preliminary Fourth Quarter and Full Year 2019 Financial Results, and Provides 2020 Financial Guidance Business Wire
Jan-09-20 04:39PM	2019 Review: Top Hedge Fund Stocks vs. Exelixis, Inc. (EXEL) Insider Monkey
Jan-08-20 10:13AM	Exelixis to Expand Prostate Cancer Cohort of Cabometyx Study Zacks

Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, Exelixis, Inc. is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, and other kinases implicated in growth and spread of cancer. It has collaboration and license agreement with Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., Roche, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Merck, Daiichi Sankyo Company, Limited, and clinical collaboration with Ipsen. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in Alameda, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hessekiel Jeffrey	EVP and General Counsel	Sep 22	Option Exercise	7.27	10,258	74,576	353,284	Sep 24 08:03 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 22	Sale	26.14	10,258	268,144	343,026	Sep 24 08:03 PM
Haley Patrick J.	EVP, Commercial	Sep 21	Option Exercise	5.82	4,680	27,238	120,251	Sep 23 08:12 PM
Haley Patrick J.	EVP, Commercial	Sep 21	Sale	26.09	4,680	122,101	115,571	Sep 23 08:12 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 16	Option Exercise	7.27	20,000	145,400	363,026	Sep 16 08:24 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 16	Sale	26.11	20,000	522,200	343,026	Sep 16 08:24 PM
Senner Christopher J.	EVP and CFO	Sep 15	Option Exercise	3.66	20,000	73,200	147,882	Sep 15 08:03 PM
Senner Christopher J.	EVP and CFO	Sep 15	Sale	25.00	20,000	500,000	127,882	Sep 15 08:03 PM
Hessekiel Jeffrey	EVP and General Counsel	Sep 08	Option Exercise	5.18	249,692	1,293,315	503,692	Sep 10 08:39 PM
COHEN CHARLES	Director	Sep 01	Option Exercise	5.82	115,396	671,605	181,375	Sep 03 08:05 PM
POSTE GEORGE	Director	Aug 14	Option Exercise	5.82	29,662	172,633	157,992	Aug 14 07:50 PM
MORRISSEY MICHAEL	President and CEO	Jul 20	Option Exercise	6.21	100,000	621,000	185,985	Jul 22 07:06 PM
Haley Patrick J.	EVP, Commercial	Jul 20	Sale	25.36	3,151	79,909	112,189	Jul 22 07:01 PM
MORRISSEY MICHAEL	President and CEO	Jul 10	Option Exercise	6.21	100,000	621,000	185,985	Jul 10 08:48 PM
MORRISSEY MICHAEL	President and CEO	Jun 19	Option Exercise	6.21	100,000	621,000	185,985	Jun 19 09:20 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 08	Option Exercise	5.51	26,000	143,260	152,531	Jun 10 08:19 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Jun 08	Sale	22.56	26,000	586,560	126,531	Jun 10 08:19 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jun 04	Option Exercise	1.70	100,000	170,000	425,963	Jun 05 08:00 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Jun 04	Sale	22.96	100,000	2,296,000	325,963	Jun 05 08:00 PM
MORRISSEY MICHAEL	President and CEO	May 29	Option Exercise	6.21	100,000	621,000	185,985	May 29 09:36 PM
Garber Alan M	Director	May 22	Sale	24.42	36,111	881,831	12,718	May 22 08:53 PM
MARCHESI VINCENT T	Director	May 21	Option Exercise	5.82	40,000	232,800	130,212	May 22 09:11 PM
MARCHESI VINCENT T	Director	May 21	Sale	24.64	40,000	985,600	90,212	May 22 09:11 PM
Haley Patrick J.	EVP, Commercial	May 20	Sale	24.99	3,151	78,743	115,340	May 22 08:17 PM
WILLSEY LANCE	Director	May 18	Option Exercise	4.58	30,000	137,400	398,273	May 20 08:36 PM
WILLSEY LANCE	Director	May 18	Sale	26.26	30,000	787,800	368,273	May 20 08:36 PM
SCANGOS GEORGE A	Director	May 18	Sale	25.96	75,000	1,947,000	714,717	May 20 08:35 PM
MORRISSEY MICHAEL	President and CEO	May 15	Option Exercise	6.21	100,000	621,000	185,985	May 15 09:29 PM
SCANGOS GEORGE A	Director	May 15	Option Exercise	5.10	51,686	263,613	789,717	May 15 08:31 PM
WILLSEY LANCE	Director	May 14	Option Exercise	5.92	15,000	88,800	383,273	May 15 08:19 PM
WILLSEY LANCE	Director	May 14	Sale	25.26	15,000	378,900	368,273	May 15 08:19 PM
PAPADOPOULOS STELIOS	Director	May 13	Option Exercise	5.82	120,791	703,004	1,173,359	May 15 08:18 PM
Hessekiel Jeffrey	EVP and General Counsel	May 13	Option Exercise	1.70	25,000	42,500	264,188	May 15 08:20 PM
Hessekiel Jeffrey	EVP and General Counsel	May 11	Option Exercise	1.90	38,006	72,211	277,194	May 11 08:36 PM
MARCHESI VINCENT T	Director	May 11	Option Exercise	4.58	30,000	137,400	112,484	May 13 09:16 PM
Hessekiel Jeffrey	EVP and General Counsel	May 11	Sale	27.09	38,006	1,029,583	239,188	May 11 08:36 PM
MARCHESI VINCENT T	Director	May 11	Sale	26.30	30,000	789,000	82,484	May 13 09:16 PM
Haley Patrick J.	EVP, Commercial	May 08	Option Exercise	1.76	21,375	37,620	139,866	May 08 09:16 PM
PAPADOPOULOS STELIOS	Director	May 08	Option Exercise	5.03	45,000	226,200	1,097,568	May 08 09:18 PM
Senner Christopher J.	EVP and CFO	May 08	Option Exercise	3.66	78,583	287,614	199,286	May 08 09:22 PM
Hessekiel Jeffrey	EVP and General Counsel	May 08	Option Exercise	1.90	25,000	47,500	264,188	May 11 08:36 PM
Hessekiel Jeffrey	EVP and General Counsel	May 08	Sale	26.04	25,000	651,000	239,188	May 11 08:36 PM
Senner Christopher J.	EVP and CFO	May 08	Sale	25.81	78,583	2,028,227	120,703	May 08 09:22 PM
Haley Patrick J.	EVP, Commercial	May 08	Sale	25.87	21,375	552,971	118,491	May 08 09:16 PM
PAPADOPOULOS STELIOS	Director	May 08	Sale	25.84	45,000	1,162,800	1,052,568	May 08 09:18 PM
Lamb Peter	EVP, Scientific Strategy & CSO	May 07	Option Exercise	5.51	50,000	275,500	176,531	May 08 09:11 PM
POSTE GEORGE	Director	May 07	Option Exercise	5.82	30,000	174,600	142,792	May 08 09:13 PM
FELDBAUM CARL B	Director	May 07	Option Exercise	4.27	31,546	134,798	40,067	May 08 09:14 PM
Senner Christopher J.	EVP and CFO	May 07	Option Exercise	3.66	21,417	78,386	142,120	May 08 09:22 PM
Hessekiel Jeffrey	EVP and General Counsel	May 07	Option Exercise	1.90	30,000	57,000	269,188	May 11 08:36 PM
Hessekiel Jeffrey	EVP and General Counsel	May 07	Sale	25.61	30,000	768,300	239,188	May 11 08:36 PM
Senner Christopher J.	EVP and CFO	May 07	Sale	25.80	21,417	552,559	120,703	May 08 09:22 PM
FELDBAUM CARL B	Director	May 07	Sale	25.02	31,546	789,281	8,521	May 08 09:14 PM
POSTE GEORGE	Director	May 07	Sale	25.61	30,000	768,300	112,792	May 08 09:13 PM
Lamb Peter	EVP, Scientific Strategy & CSO	May 07	Sale	25.54	50,000	1,277,000	126,531	May 08 09:11 PM
MORRISSEY MICHAEL	President and CEO	May 06	Option Exercise	1.70	285,284	484,983	371,269	May 08 09:10 PM
MORRISSEY MICHAEL	President and CEO	Apr 27	Option Exercise	1.70	285,000	484,500	370,985	Apr 29 08:10 PM
SCANGOS GEORGE A	Director	Apr 24	Sale	26.24	15,000	393,600	738,031	Apr 24 08:24 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 23	Option Exercise	1.70	100,000	170,000	425,122	Apr 24 08:25 PM
Haley Patrick J.	EVP, Commercial	Apr 23	Option Exercise	1.70	5,000	8,500	121,873	Apr 24 08:22 PM
MORRISSEY MICHAEL	President and CEO	Apr 23	Option Exercise	5.51	250,000	1,377,500	335,985	Apr 24 08:41 PM
SCANGOS GEORGE A	Director	Apr 23	Sale	25.99	100,000	2,598,635	753,031	Apr 24 08:24 PM
Haley Patrick J.	EVP, Commercial	Apr 23	Sale	26.00	5,000	130,000	116,873	Apr 24 08:22 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Apr 23	Sale	26.00	100,000	2,600,000	325,122	Apr 24 08:25 PM
SCANGOS GEORGE A	Director	Apr 22	Sale	25.05	4,200	105,210	853,031	Apr 22 08:50 PM
MORRISSEY MICHAEL	President and CEO	Apr 21	Option Exercise	5.51	220,000	1,212,200	393,064	Apr 22 09:53 PM
SCANGOS GEORGE A	Director	Apr 21	Sale	25.04	5,800	145,232	857,231	Apr 22 08:50 PM
MORRISSEY MICHAEL	President and CEO	Apr 20	Option Exercise	5.51	240,000	1,322,400	325,985	Apr 22 09:53 PM
Haley Patrick J.	EVP, Commercial	Apr 20	Option Exercise	1.70	5,000	8,500	121,873	Apr 22 08:49 PM
SCANGOS GEORGE A	Director	Apr 20	Sale	23.89	50,000	1,194,637	863,031	Apr 22 08:50 PM
Haley Patrick J.	EVP, Commercial	Apr 20	Sale	24.00	5,000	120,000	116,873	Apr 22 08:49 PM
SCANGOS GEORGE A	Director	Apr 15	Sale	18.31	25,000	457,750	913,031	Apr 17 08:11 PM
SCANGOS GEORGE A	Director	Apr 08	Sale	18.35	7,065	129,643	938,031	Apr 09 08:20 PM
SCANGOS GEORGE A	Director	Apr 07	Sale	18.25	16,435	299,939	945,096	Apr 09 08:20 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 06	Option Exercise	5.51	50,000	275,500	176,531	Apr 08 08:12 PM
Lamb Peter	EVP, Scientific Strategy & CSO	Apr 06	Sale	17.26	50,000	863,000	126,531	Apr 08 08:12 PM
WYSZOMIERSKI JACK L	Director	Apr 03	Option Exercise	5.03	45,000	226,200	175,526	Apr 03 08:38 PM
WYSZOMIERSKI JACK L	Director	Apr 03	Sale	16.57	13,848	229,461	161,678	Apr 03 08:38 PM
SCANGOS GEORGE A	Director	Mar 31	Sale	18.06	1,500	27,090	961,531	Apr 02 08:08 PM
Haley Patrick J.	EVP, Commercial	Mar 20	Sale	15.37	4,318	66,368	116,873	Mar 20 09:03 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Mar 04	Option Exercise	1.70	100,000	170,000	425,122	Mar 06 08:01 PM
MORRISSEY MICHAEL	President and CEO	Mar 04	Option Exercise	5.51	50,000	275,500	135,985	Mar 06 08:07 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Mar 04	Sale	19.40	100,000	1,940,000	325,122	Mar 06 08:01 PM
FELDBAUM CARL B	Director	Mar 03	Option Exercise	5.62	38,000	213,720	46,521	Mar 05 08:00 PM
FELDBAUM CARL B	Director	Mar 03	Sale	18.84	38,000	716,013	8,521	Mar 05 08:00 PM
COHEN CHARLES	Director	Feb 28	Option Exercise	5.03	45,000	226,200	65,979	Mar 02 09:14 PM
MORRISSEY MICHAEL	President and CEO	Feb 26	Option Exercise	5.51	25,000	137,750	110,985	Feb 28 08:05 PM
MORRISSEY MICHAEL	President and CEO	Feb 26	Sale	18.91	25,000	472,850	85,985	Feb 28 08:05 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 19	Option Exercise	5.51	40,000	220,400	365,122	Feb 21 08:00 PM
MORRISSEY MICHAEL	President and CEO	Feb 19	Option Exercise	0.00	25,000	0	110,985	Feb 21 08:03 PM
Haley Patrick J.	EVP, Commercial	Feb 19	Option Exercise	0.00	5,000	0	126,191	Feb 21 08:17 PM
Haley Patrick J.	EVP, Commercial	Feb 19	Sale	22.00	5,000	110,000	121,191	Feb 21 08:17 PM
MORRISSEY MICHAEL	President and CEO	Feb 19	Sale	21.75	25,000	543,750	85,985	Feb 21 08:03 PM
Schwab Gisela	Pres, Prod Dev & Med Aff & CMO	Feb 19	Sale	21.50	40,000	860,000	325,122	Feb 21 08:00 PM
SCANGOS GEORGE A	Director	Feb 18	Sale	20.73	50,000	1,036,500	963,031	Feb 21 08:28 PM
Garber Alan M	Director	Feb 14	Sale	21.02	12,500	262,750	48,829	Feb 14 08:36 PM
MORRISSEY MICHAEL	President and CEO	Feb 13	Option Exercise	5.51	25,000	137,750	110,985	Feb 14 08:48 PM
MORRISSEY MICHAEL	President and CEO	Feb 13	Sale	20.11	25,000	502,750	85,985	Feb 14 08:48 PM
SCANGOS GEORGE A	Director	Feb 12	Sale	20.02	21,000	420,420	1,013,031	Feb 12 08:21 PM
SCANGOS GEORGE A	Director	Feb 11	Sale	20.14	4,000	80,560	1,034,031	Feb 12 08:21 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience